Interim analyses of two phase 2b studies of volixibat support its use as potential treatment for patients with primary biliary cholangitis and primary sclerosing cholangitis, according to a press release from Mirum Pharmaceuticals.
“The results of the interim analyses are very impressive as they confirm the potential of volixibat in targeting bile acids in PBC and PSC,” study investigator Kris Kowdley, MD, professor at Washington State University and director of Liver Institute Northwest, said in the release. “I look forward to seeing the final data with the goal of having